Antimicrobial susceptibility of H pylori strains obtained from Paraguayan patients;Susceptibilidad a antibióticos de cepas paraguayas de Helicobacter pylori aisladas de pacientes con enfermedad gastro-duodenal

Revista Medica de Chile

Volumn 135, Issue 8, 2007, Pages 1009-1014

  Fariña, Norma ^a   Kasamatsu, Elena ^a   Samudio, Margarita ^a   Morán, Miryam ^a   Sanabria, Rosa ^a   Laspina, Florentina ^a  

^a UNIVERSIDAD NACIONAL DE ASUNCIÓN   (Paraguay)

Author keywords

Anti bacterial agents; Biopsy; Helicobacter pylori

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; CLARITHROMYCIN; METRONIDAZOLE;

ADOLESCENT; ADULT; AGED; ARTICLE; DRUG EFFECT; FEMALE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; MULTIDRUG RESISTANCE; PARAGUAY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMOXICILLIN; ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PARAGUAY;

EID: 36249020826     PISSN: 00349887     EISSN: 07176163     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. FERNÁNDEZ H. Helicobacter pylori. Un nuevo agente a ser considerado en patología gástrica. Cuad Cir 1993; 7: 91-7.
2. MARSHALL BJ, WARREN JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; i: 1311-15.
3. DUNN B, COHEN H, BLASER M. Helicobacter pylori. Clin Microbiol Rev 1997; 10(4): 720-41.
4. KASAMATSU E, CENTURIÓN M, MACCHI H, LATERZA O, ORTIZ VILLALBA J, MARTÍNEZ C. Evaluación de las lesiones histológicas en las gastritis crónicas asociadas a Helicobacter pylori. Ann Rep IICS 1995: 21-37.
5. Internacional Agency for Research on Cancer, IARC monographs on the evaluation of carcinogenic risks to humans. Schistosomes, Liver Flukes and Helicobacter pylori. Lyon, IARC 1994; 61: 177-240.
6. CORREA P. Helicobacter pylori and gastric carcinogenesis. Am J Surg Pathol 1995; 19 Suppl 1: S37-43.
7. MERA R, FONTHAM TH, BRAVO LE, BRAVO JC, PIAZUELO MB, CAMARGO MC, CORREA P. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2006; 55(7): 1536-40.
8. CUCHÍ BURGOS E, FORNÉ BARDERA M, QUINTANA RIERA S, LITÉ LITÉ J, GARAU ALEMANY J. Evolución de la sensibilidad de 235 cepas de Helicobacter pylori entre 1995 y 1998 e impacto del tratamiento antibiótico. Enferm Infecc Microbiol Clin 2002; 20(4): 157-60.
9. ALARCÓN T, BAQUERO M, DOMINGO D, LÓPEZ-BREA M, ROYO G. Diagnóstico microbiológico de la infección por Helicobacter pylori. 2004. Procedimientos en Microbiología Clínica. SEIMC, Madrid 2004.
10. GLUPCZYNSKI Y, BURETTE A. Clinical Review: drug therapy for H. pylori infection: problemas and pitfalls. Am J Gastroenterol 1990; 85: 1545-51.
11. GODDARD AF, LOGAN RPH. Antimicrobial resistance and Helicobacter pylori. J Antimicrob Chemother 1996; 37: 639-43.
12. LOO V, FALLONE C, DE SOUZA E, LAVALLÉE J, BARKUN A. In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole. J Antimicrob Chemother 1997; 40: 881-3.
13. FLORES S, OPAZO H, VALDERRAMA D, AGUILERA R, MARCHESE A, VALDERRAMA S. Terapia triple de corto tiempo con azitromicina, amoxicilina y omeprazol para la erradicación de Helicobacter pylori. Rev Méd Chile 2000; 128: 509-12.
14. KALACH N, BERGERET M, BENHAMOU PH, DUPONT C, RAYMOND J. High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children. J Clin Microbiol 2001; 39: 394-7.
15. National Committee for Clinical Laboratory Standards. 2000. Performance standards for antimicrobial susceptibility testing and approved standard M7-A5. Informational supplement M100-S10.22. National Committee for Clinical Laboratory Standards, Wayne, Pa.
16. BEST LM, HALDANE DJM, KEELAN M, TAYLOR DE, THOMSON ABR, LOO V ET AL. Multilaboratory Comparison of Proficiencies in Susceptibility Testing of Helicobacter pylori and Correlation between Agar Dilution and E Test Methods. Antimicrob Agents Chemother 2003; 47: 3138-44.
17. QUEIROZ DMM, MENDES EN, ROCHA GA. Indicator medium for isolation of Campylobacter pylori. J Clin Microbiol 1987; 25: 2378-9.
18. QUEIROZ DM, MENDES EN, ROCHA GA, MOURA SB, RESENDE LM, BARBOSA AJ ET AL. Effect of Helicobacter pylori eradication on antral gastrin and somatostatin-immunoreactive cell density and gastrin and somatostatin concentrations. Scand J Gastroenterol 1993; 28: 858-64.
19. GLUPCZYNSKI Y, BROUTET N, CANTAGREL A, ANDERSEN LP, ALARCON V, LÓPEZ-BREA V, MEGRAUD F. Comparison of the E test and agar dilution method for antimicrobial suceptibility testing of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2002; 21: 549-52.
20. PICCOLOMINI R, BONAVENTURA G DI, CATAMO G, CARBONE F, NERI M. Comparative evaluation of the E test, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents. J Clin Microbiol 1997; 35: 1842-6.
21. GONZÁLEZ C, GARCÍA A, DAROCH F KAWAGUCHI F, SOLAR H, RIVERA N, VEGA E. Susceptibilidad in vitro de cepas de Helicobacter pylori: aislamiento de cepas resistentes a claritromicina. Rev Méd Chile 2001; 129: 643-6.
22. SOLL AH. Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. JAMA 1996; 275: 622-9.
23. VÁSQUEZ Y, VALDÉS R, GUMAN JJ, MC DONALD TU, WESTBLOM D, BERG D ET AL. Metronidazole and clarithromycin resistance in Helicobacter pylori. Determined by measuring MICs of Antimicrobial agents in color indication egg yolk agar in a miniwell format. J Clin Microbiol 1996; 34: 1232-4.
24. DORE MP, SEPÚLVEDA AR, MURA I, REALDI G, OSATO MS, GRAHAM DY. Explanation for variability of omeprazole amoxicillin therapy? Tolerance of Helicobacter pylori to amoxicillin. Gastroenterol 1997; 112: A105.